Thromboxane synthase (TXAS) is a "non-classical" cytochrome P450. Without any need for an external electron donor, or for a reductase or molecular oxygen, it uses prostaglandin H 2 (PGH 2 ) to catalyze either an isomerization reaction to form thromboxane A 2 (TXA 2 ) or a fragmentation reaction to form 12-L-hydroxy-5,8,10-heptadecatrienoic acid and malondialdehyde (MDA) at a ratio of 1:1:1 (TXA 2 :heptadecatrienoic acid:MDA). We report here kinetics of TXAS with heme ligands in binding study and with PGH 2 in enzymatic study. We determined that 1) binding of U44069, an oxygen-based ligand, is a two-step process; U44069 first binds TXAS, then ligates the hemeiron with a maximal rate constant of 105-130 s ; the rate of catalytic conversion of PGH 2 to TXA 2 or MDA was at least 15,000 s ؊1 and the lower limit of the rates for products release was 4,000 -6,000 s
M
؊1 s ؊1 and 1.5 ؋ 10
؊1 s ؊1 for imidazole and clotrimazole, respectively, followed by a slow conformational change with off-rate constants of 8.8 s ؊1 and 0.53 s
؊1
, respectively. The results of our binding study indicate that the TXAS active site is hydrophobic and spacious. In addition, steady-state kinetic study revealed that TXAS consumed PGH 2 at a rate of 3,800 min ؊1 and that the k cat /K m for PGH 2 consumption was 3 ؋ 10 6 M ؊1 s
. Based on these data, TXAS appears to be a very efficient catalyst. Surprisingly, rapid-scan stopped-flow experiments revealed marginal absorbance changes upon mixing TXAS with PGH 2 , indicating minimal accumulation of any heme-derived intermediates. Freeze-quench EPR measurements for the same reaction showed minimal change of heme redox state. Further kinetic analysis using a combination of rapid-mixing chemical quench and computer simulation showed that the kinetic parameters of TXAS-catalyzed reaction are: PGH 2 bound TXAS at a rate of 1.2-2.0 ؋ 10 7 M ؊1 s
; the rate of catalytic conversion of PGH 2 to TXA 2 or MDA was at least 15,000 s ؊1 and the lower limit of the rates for products release was 4,000 -6,000 s
. Given that the cellular PGH 2 concentration is quite low, we concluded that under physiological conditions, the substrate-binding step is the rate-limiting step of the TXAS-catalyzed reaction, in sharp contrast with "classical" P450 enzymes.
Thromboxane A 2 (TXA 2 ) 1 is a potent inducer of vasoconstriction and platelet aggregation. It is believed to be a crucial factor contributing to a variety of cardiovascular and pulmonary diseases such as atherosclerosis, myocardial infarction, and primary pulmonary hypertension (1, 2) . TXA 2 is rather labile, being hydrolyzed to the biologically inactive thromboxane B 2 (TXB 2 ) with a half-life of about 30 s in aqueous solution at 37°C (3) . Its biosynthesis is accomplished by thromboxane synthase (TXAS) using prostaglandin H 2 (PGH 2 ) as the substrate. Notably, the formation of TXA 2 is accompanied by those of 12-L-hydroxy-5,8,10-heptadecatrienoic acid (HHT) and malondialdehyde (MDA) at a ratio of 1:1:1 (4) (Scheme 1). The biological functions of MDA and HHT are unclear. However, MDA can form adducts with lysine residues of proteins or with amine head groups of phospholipids and its adducts have been detected in atherosclerotic lesions of human aorta (5) . It was also shown to participate in the formation of an important endogenous DNA adduct which may contribute to the etiology of human genetic disease and cancer (6) .
TXAS is a member of the cytochrome P450 superfamily and is associated with endoplasmic reticulum (4, 7) . Human TXAS was assigned as CYP 5A1. Unlike other microsomal P450s that require the ubiquitous P450 reductase to shuttle electrons for the mono-oxygenation reaction, TXAS undergoes an isomerization reaction without reductase or molecular oxygen. A "classical" P450 accepts an electron from the reductase and converts heme iron to the Fe(II) state, followed by binding of molecular oxygen and another one-electron reduction. The subsequent steps, including oxygen bond cleavage and oxidation of the substrate, occur rapidly and have been difficult to resolve (8 , respectively (9) . The intermediates of the later steps in the P450 cam reaction were well characterized in a recent time-resolved x-ray crystallographic study in which the presence of an oxyferryl intermediate after breakdown of molecular oxygen was identified (10) .
TXAS, which uses an endoperoxide as the substrate, apparently undergoes a different mechanism. Hecker and Ullrich (11) proposed a mechanistic model for TXAS involving a homolytic scission of PGH 2 that led to the formation of heme-Fe(IV) and alkoxy radical intermediates for enzyme and substrate species, respectively. In the present study, we attempted to characterize the intermediates of the TXAS reaction employing optical and EPR spectroscopies. EPR studies failed to identify any radical species. Stopped-flow spectroscopy revealed no significant absorbance changes at the heme center. Further ki-netic analysis using the rapid-mixing chemical quench and computer simulation showed that the substrate-binding step is the rate-limiting step of TXAS-catalyzed reaction, and that the catalytic conversion of PGH 2 to TXA 2 or MDA by TXAS was remarkably fast.
EXPERIMENTAL PROCEDURES
Chemicals-Arachidonic acid was obtained from NuChek Prep (Elysian, MN). U44069 (15-hydroxy-9,11-(epoxymethano)prosta-5,13-dienoic acid) was from Cayman Chemical (Ann Arbor, MI). Isopropyl alcohol used for PGH 2 preparation was first treated with crystals of sodium sulfate, followed with 12-mesh t.h.e. desiccant (EM Science, Gibbstown, NJ). [1- 14 C]Arachidonic acid (55 mCi/mmol) was obtained from Amersham Pharmacia Biotech (Arlington Heights, IL). 4,6-Dihydroxy-2-mercaptopyrimidine, also known as thiobarbituric acid (TBA), was purchased from Fisher Scientific.
Preparation of PGH 2 -PGH 2 was prepared following published procedures with some modifications (12) . Briefly, 1 mg of arachidonic acid was incubated with 8 ml of 0.1 M potassium P i , pH 7.2 (pre-saturated with oxygen), containing 0.5 mM phenol and 1 mM hemin. The reaction was initiated by adding 300 l of prostaglandin synthase-1 (about 6 -8 mg of protein/ml) obtained from the supernatant fraction of Tween 20-treated ram seminal microsomes. The reaction mixture was then incubated, with stirring, for 2 min at 23°C, and then acidified with 0.8 ml of 2 M citric acid. PGH 2 was immediately extracted twice with 10 ml of ether:hexane mixture (v/v, 5:1). The combined organic layers were dried over crystals of sodium sulfate, concentrated by purging with nitrogen gas and replaced with the HPLC solvent (hexane:isopropyl alcohol:acetonitrile:acetic acid, 95:5:0.05:0.05) to a final volume of 0.5 ml. The extracts were then filtrated through a 0.5-m Millex-LCR 4 filter (Millipore, Bedford, MA), concentrated to 0.2-ml and applied to a straight-phase silica HPLC column (Waters Spherisorb S5W, 10 mm ϫ 250 mm). The HPLC system was interfaced to a Waters Millennium 32 Program (Waters, Milford, MA). The column was eluted isocratically with the HPLC solvent at a flow rate of 1 ml/min and the eluent was simultaneously monitored at 200 and 234 nm with a Waters 2487 dual wavelength absorbance detector. PGH 2 eluted as a discrete band with a retention time of about 16 min, as indicated by the appearance of a 200-nm peak, which was not seen when monitored at 234 nm. Fractions were collected, concentrated under nitrogen gas and stored at Ϫ70°C. PGH 2 was stable under this condition for at least 6 months. In preparing PGH 2 for stopped-flow and EPR experiments, HPLC solvent was evaporated under nitrogen gas prior to use and immediately replaced with isopropyl alcohol.
Quantitation of PGH 2 was carried out by including 0. Protein Purification and Activity Assay-A recombinant human TXAS, with a histidine-tag at the carboxyl terminus, was expressed in Escherichia coli and purified by nickel and octyl column chromatography, as previously described for the wild-type TXAS (13) . TXAS was concentrated by ultrafiltration and dialyzed against buffer containing 50 mM potassium P i , pH 7.4, 10% glycerol, and 0.005% Emulgen 913. TXAS activity was measured by spectroscopic assay for the formation of MDA. TXAS was added to 300 l of 50 mM potassium P i , pH 7.4, and 0.1% Lubrol. The reaction was initiated by adding 40 M PGH 2 and MDA formation was followed by absorbance increase at 268 nm at 23°C using a Shimadzu UV-2401PC Spectrophotometer. TXAS concentration was determined by absorbance at 418 nm using the extinction coefficient of 100 mM Ϫ1 cm Ϫ1 (13) . Alternatively, TXAS activity was measured by a coupled assay as previously described (13), using arachidonic acid and ovine prostaglandin H synthase-1 to generate PGH 2 in situ. Quantitation of TXB 2 , the stable hydration product of TXA 2 , was carried out by radioimmunoassay (14) .
Stopped-flow and EPR Spectroscopy-Stopped-flow spectroscopy was performed, under the conditions as described in the figure legends, on an Applied Photophysics model SX-18MV. In the ligand binding studies, TXAS and ligands prepared in 50 mM potassium P i , pH 7.4, 10% glycerol, and 0.005% Emulgen 913 were reacted by equal mixing mode at 23°C. In the TXAS-catalyzed reaction, TXAS was kept in the aforementioned buffer but PGH 2 was dissolved in isopropyl alcohol prior to the experiments. A 10:1 (TXAS:PGH 2 ) mixing was used. An independent experiment showed that up to 10% of isopropyl alcohol had no effect on TXAS activity. Kinetic data were collected either at the single wavelength mode or by photodiode array detector to record spectra over 300-700 nm.
For EPR measurements, TXAS and PGH 2 were mixed using a System 1000 rapid quench apparatus (Update Instrument Inc., Madison, WI). About 12 M TXAS was loaded in two 7.2-ml syringes and PGH 2 was loaded in a 0.5-ml syringe to give a 29:1 mixing ratio. Reactants once passed via a Wiskind 4-grid mixer were directly injected into a pre-chilled EPR tube and immediately dropped into a dry ice-acetone bath. EPR spectra were recorded at liquid helium temperature on a Varian E-6 spectrometer.
Rapid-mixing Chemical Quench Studies-Rapid quench kinetic studies were also carried out using a System 1000 rapid quench apparatus. TXAS was in 50 mM potassium P i , pH 7.4, 10% glycerol, and 0.005% Emulgen 913 whereas PGH 2 was in the HPLC solvent. TXAS was top-loaded into a 7.2-ml syringe and PGH 2 was loaded into a 0.5-ml syringe, thus giving a TXAS: PGH 2 mixing ratio of 14.4:1. Reaction time was controlled either by using aging tubes of various lengths (for reactions of less than 150 ms) or a programmed push-push mechanism. Reactions were carried out at room temperature (21-23°C). The concentration of TXAS, after mixing, was kept at 5 M and those of PGH 2 were at 5, 15, and 50 M. After the indicated time points, the reactions were quenched by mixing through the second mixer, with an equal volume (ϳ200 l) of a solution containing 10% trichloroacetic acid and 0.3 M HCl loaded in a second 7.2-ml syringe. The ram velocity of the instrument was operated at 0.8 cm/s for both rapid-mixing and chemical quench steps.
Quantitation of MDA thus formed was determined using the TBA assay as previously described (15) . Briefly, 200 l of the quenched mixture was centrifuged at 12,000 ϫ g for 5 min to remove denatured proteins, and 180 l of the supernatant was added to 180 l of TBA solution (0.53% TBA in 50 mM potassium P i , pH 7.4). The sample was heated at 70°C for 30 min and then cooled at room temperature for 10 min before measuring the absorbance at 532 nm. The concentration of MDA-TBA adduct was calculated based on ⑀ 532 ϭ 156 mM Ϫ1 cm Ϫ1 (16) . Computer Simulation-The ScoP Program (Simulation Resources Inc., Redlands, CA) was used for kinetic simulation of the proposed model shown in Table I . The assignments of rate constants were tested by comparing with the experimental data and will be detailed under "Results."
RESULTS

Binding of U44069 to TXAS-U44069
is a stable TXAS substrate analog with the C-11 oxygen of PGH 2 replaced by a carbon atom whereas the C-9 oxygen remains intact. It was shown previously that U44069 interacted with TXAS by replacing the initial heme ligand (most likely water) with the C-9 oxygen atom (11). Binding of U44069 to TXAS induced a blue shift in the Soret peak and equilibrium dissociation constant was determined to be 28 M
SCHEME 1
Thromboxane Synthase Kinetic Studyfrom the difference spectra that had a peak at 409 nm and a trough at 426 nm (13) . To investigate the mechanism of substrate binding to TXAS, we carried out stopped-flow spectroscopy using U44069 as the ligand and monitored the absorbance changes at 409 and 426 nm. Fig. 1A described stopped-flow traces observed upon mixing 2 M TXAS with 10-60 M U44069. A control sample, where TXAS was mixed with buffer alone, resulted in no significant absorbance changes (data not shown). For all concentrations of U44069 used in these kinetic measurements, a single exponential absorbance change was observed for both wavelengths. The pseudo-first order rate constant, k obs , was obtained by an exponential fitting algorithm. Plots of k obs monitored at 409 and 426 nm versus U44069 concentrations followed Michaelis-Menten-type kinetics (Fig. 1B) , suggesting that binding of U44069 to TXAS is a two-step binding process,
and the k obs can be represented by Equation 2 (17),
The single exponential kinetics of the absorbance change suggested that we were monitoring only one step of the two-step binding process, i.e. the conversion of (E:U44069) 1 Ϫ to TXAS induced a red shift in the Soret peak from 418 to 447 nm. Under pseudo first-order conditions, k obs were obtained for each cyanide concentration from the exponential time courses at 447 nm. Fig.  2A shows the traces of absorbance changes for complex formation displaying monophasic exponential character. The inset of Fig. 2A shows that k obs is linearly related to CN Ϫ concentrations, suggesting a simple, one-step binding reaction.
The second order rate constant, k on , obtained form the plot is 2.4 M Ϫ1 s Ϫ1 . The intercept of this plot, 0.112 s Ϫ1 , represents dissociation rate constant (k off ). The ratio of these two rate constants, k off /k on , gives a value for dissociation constant (K d ) of TXAS-cyanide complex of 47 mM, comparable to the K d value (7.3 Ϯ 0.6 mM) determined from the optical equilibrium titration with CN Ϫ (data not shown). Previous work has shown that imidazole binds TXAS and causes the shift of the Soret peak to 434 nm with K d of 33 M (13). In the present stopped-flow studies, absorbance changes at 434 nm were followed after mixing TXAS with excess imidazole (Fig. 2B) . In contrast to U44069 and cyanide, all the stopped-flow traces from the imidazole binding kinetics were best-fitted using two exponential terms. The amplitude of the first phase (fast phase) accounted for most of the total absorbance changes (62-81%) and increased as the concentration of imidazole increased, whereas the amplitude of the second phase (slow phase) was essentially unchanged over the range of 50 -1000 M imidazole. When plotted against the concentrations of imidazole, k obs of the fast phase reveals a linear dependence whereas k obs of the slow phase is independent of imidazole concentrations (inset of Fig. 2B ). These results indicated a two-step binding reaction: the first step requires that the original heme ligand of TXAS be replaced by imidazole, and this step is also accompanied by a larger absorbance change, whereas the second step is presumably a slow conformational change in which heme-bound imidazole is re-oriented to reach the final conformation. k on , and the y intercept, 8.84 s Ϫ1 for k off . The rate constants of slow phase were in the range of 0.84 -1.40 s Ϫ1 . Clotrimazole is an imidazole derivative heme ligand. The carbon atom at the imidazole N-1 position is bonded to three phenyl rings with vertical and horizontal dimensions of ϳ8.5 and 9.5 Å, as compared with 2.8 and 4.2 Å for imidazole. We have shown that the clotrimazole-induced difference spectra had a peak and a trough at 431 and 410 nm, respectively (13) . Stopped-flow analysis following the absorbance changes at 431 nm showed that the kinetics of clotrimazole binding to TXAS was very similar in character to that achieved by imidazole. Two kinetic phases were observed upon binding (Fig. 2C) , and k obs of the first phase (fast phase) was linearly dependent on clotrimazole over the concentrations of 3.1-18.7 M (inset of Fig. 3C ). Higher clotrimazole concentrations were unachievable due to the low solubility of the ligand in the reaction buffer. The amplitude of the fast phase accounted for 63-72% of the total observed amplitude. The second-order rate constant and the intercept obtained from the plot of k obs versus ligand concentrations were 1.51 ϫ 10 5 M Ϫ1 s Ϫ1 and 0.53 s Ϫ1 , respectively. Similar to imidazole, the amplitudes and rate constants of the clotrimazole-TXAS binding slow phase (i.e. ϳ0.2-0.4 s Ϫ1 ) were concentration independent. In a similar experimental set-up where absorbance changes were monitored at 410 nm, stopped-flow traces were nearly mirror image to those monitored at 431 nm and kinetic parameters obtained from both wavelengths were almost identical (data not shown).
Steady-state Kinetic Analysis of TXAS-We reported previously that the recombinant TXAS had a K m of 20 M PGH 2 and a V max of 12 mol of TXA 2 formed/min/mg of protein, as compared with the native platelet TXAS which has a K m of 22 M PGH 2 and a V max of 24 mol of TXA 2 or MDA formed/min/mg of protein (4, 18) . It should be noted that these kinetic parameters were determined by different assay systems. We used the coupled assay that included prostaglandin H synthase-1 and arachidonic acid, whereas the other groups added PGH 2 directly to the assay mixture instead. In the present study, we measured the TXAS activity by following the MDA formation at 268 nm (⑀ 268 ϭ 31.5 mM Ϫ1 cm
Ϫ1
) after adding PGH 2 to the assay buffer. The initial rates were calculated from the slope of the first 10 -20 s of the reaction. Nonlinear least-square analysis of TXAS activity versus PGH 2 concentrations (1.5 to 240 M), as shown in Fig. 3 , gave the recombinant TXAS a K m of 21.3 Ϯ 2.2 M and a V max of 32.6 Ϯ 0.8 mol of MDA/min/mg of protein, equivalent to a turnover number, k cat , of 1960 min
.
Stopped-flow and Freeze-quench EPR Spectroscopic
Studies-Although steady-state kinetic analysis can provide rate parameters such as K m and k cat , it cannot be used to dissect each step in the catalytic cycle. To test whether heme chemistry is the rate-limiting step of TXAS reaction, transient kinetic measurement were conducted. Our initial attempt to study the role of heme iron involved in TXAS catalysis was carried out by following the absorbance changes at 418 nm in a stopped-flow apparatus. Several conditions were tested: TXAS concentrations (1-4 M), PGH 2 concentrations (1-10-fold molar excess of TXAS) and temperature (4°C and room temperature). Nevertheless, no significant absorbance changes were observed in all the conditions we tested (data not shown). We then expanded our observation using rapid-scan stopped flow spectroscopy. Stopped flow recording of reaction time from instrument dead- time to 1 s upon mixing 4 M TXAS with 1-, 3-, and 10-fold molar excess of PGH 2 , again, revealed no significant absorbance changes over 300 -700 nm. As described below, 1 s of reaction time was sufficient to convert nearly all the substrate to products. Fig. 4A shows that the absorption spectra of TXAS interaction with 3-fold molar excess of PGH 2 from 6 to 210 ms are nearly indistinguishable.
A TXAS reaction mechanism proposed by Hecker and Ullrich (11) involved a homolytic scission of O-O bond of PGH 2 to form an alkoxy radical. To test this key step in the postulated TXAS reaction mechanism, we employed freeze-quench EPR spectroscopy in an attempt to establish the chemical structure of alkoxy radical during TXAS catalysis. Reactions were carried out at 23°C by a rapid-freeze apparatus that mixed 12 M TXAS with PGH 2 (final concentrations of ϳ50 and 100 M). The apparatus allowed the reactants to interact for about 10 ms and the reaction mixture was immediately freeze-trapped in a dry iceacetone bath, which took less than 2 s to freeze the samples. Samples obtained by this method were stored in liquid nitrogen prior to undertaking the EPR spectroscopic study. EPR spectra of PGH 2 -treated TXAS, as shown in Fig. 4B , revealed no differences from that of the isopropyl alcohol-treated control or from resting TXAS (data not shown).
Since PGH 2 is very labile in water having half-life of about 5 min (19), we hence examined whether PGH 2 was degraded due to the contamination of trace amounts of water in isopropyl alcohol. PGH 2 stock was analyzed before and after the stoppedflow and EPR experiments by following the capacity of TXAScatalyzed MDA and HHT formation. The degree of PGH 2 degradation varied from 10 to 40%; lower PGH 2 concentrations were degraded faster. Despite the instability of PGH 2 during the experiments, the remaining concentrations of PGH 2 were still sufficient to interact with TXAS and thus allow us to Table I. FIG. 4. TXAS-catalyzed reaction analyzed by rapid-scan stopped-flow and EPR spectroscopy. In these experiments, TXAS was present in 50 mM potassium P i , pH 7.4, 10% glycerol, and 0.005% Emulgen 913, and PGH 2 was in isopropyl alcohol. Panel A, spectral changes of TXAS followed by a rapid scan spectrophotometer after mixing PGH 2 at 23°C. TXAS (4.2 M) was mixed, in a 10:1 mixing mode, with 130 M PGH 2 and spectra were recorded with 2.56-ms intervals and 3.3-nm increments. Selected spectra of the reactions took place at the times indicated are shown. Panel B, EPR spectra of TXAS after mixing, in an approximate 29:1 ratio, with PGH 2 . TXAS (12 M) was mixed with PGH 2 (indicated as final concentrations) at 23°C. Anisotropic g values are shown. EPR conditions were as follows: power, 1 milliwatt; modulation amplitude, 10 G; and temperature, 11 K.
observe the signal changes if the proposed reaction mechanism was correct. The only other possibility is that the TXAS-catalyzed reaction takes place so rapidly that it exceeds the stopped-flow spectrophotometer reaction rate limit and therefore cannot be measured.
Rapid-mixing Chemical Quench Studies-To gain further understanding of the kinetic mechanism by which TXAS converts PGH 2 to TXA 2 and MDA, we performed rapid-mixing experiments using chemical quench techniques as described under "Experimental Procedures." Durations of reaction were allowed to carry out ranging from 3.2 ms to 1 s. The enzymatic products, i.e. TXB 2 and MDA, were quantitatively determined by radioimmunoassay and TBA assay, respectively. Blank TXB 2 and MDA were obtained by manually mixing TXAS, HPLC solvent without PGH 2 , and the quenching solution. PGH 2 was kept in the HPLC solvent to avoid degradation, and TXAS activity, in a control experiment, was not affected by up to 10% of HPLC solvent concentration. The remaining PGH 2 in the syringe was collected after the rapid quench experiments and was assayed for its capacity to synthesize MDA and HHT by TXAS. Little PGH 2 was degraded (Ͻ5%) during the entire experimental period.
In all three levels of PGH 2 concentration tested, more than 30% of PGH 2 was converted to the products at the shortest reaction time, 3.2 ms, and nearly all the substrate was consumed at 0.3 s. Fig. 5 shows that formation of TXB 2 , MDA, and combination of both products at the given reaction time using 1-(panel A), 3-(panel B), and 10-fold (panel C) molar ratio of PGH 2 :TXAS. Further kinetic analysis of this TXAS-catalyzed reaction was conducted by computer simulation of a simplified reaction mechanism in which PGH 2 was converted to TXA 2 and MDA at the same rate (k 2 as shown in Table I , Scheme 2). Optimal simulations using the ScoP program were done with the following settings. The k 1 and k Ϫ1 were varied while keeping k 1 /k Ϫ1 ϭ 20 M, comparable to the dissociation constant of TXAS and U44069. Because the TXAS-catalyzed reaction is thought to be irreversible, k Ϫ2 , k Ϫ3 , and k Ϫ4 were set at 0.01 s
Ϫ1
, an arbitrarily small number. The values of k 1 , k Ϫ1 , k 2 , k 3 , and k 4 produced from the optimal simulation for 1-, 3-, and 10-fold rations of PGH 2 :TXAS are summarized in Table I . We also tested this kinetic mechanism by comparing the simulation results and experimental data obtained from the stopped-flow experiments that followed the absorbance changes at 418 nm. In these experiments, MDA was produced at higher levels than TXB 2 with a molar ratio of 0.6:0.4, in contrast to the previous reports that had a MDA:TXB 2 ratio of 1:1. This may be because TXB 2 was collected under very acidic conditions (10% trichloroacetic acid and 0.3 M HCl) and was slightly degraded. Optimal simulation gave the rate constants of MDA and TXB 2 release as 6,000 s Ϫ1 and 4,000 s Ϫ1 , respectively. These values are also the lower limits since smaller values shift the minimum of the A 418 kinetic data toward longer time points. Simulation results for changes in concentration of TXAS, MDA, and TXB 2 are in agreement with the experimental data and are presented in Fig. 5 . These results clearly indicated that the reaction intermediates are very shortlived, and the substrate is rapidly converted to products once it binds TXAS. DISCUSSION TXAS, as a resting enzyme, has a typical low spin P450 heme with an oxygen-based distal ligand (4, 13) . Several types of heme ligands including U44069 (oxygen-based ligand), imidazole, clotrimazole (both are nitrogen-based ligands), and cyanide (carbon-based ligand) were studied to determine their kinetic binding characteristics with TXAS using stopped-flow spectroscopy. All these ligands caused Type II spectral changes, indicating that the exogenous ligands formed a low-spin coordinate heme complex. However, their binding kinetics to TXAS were quite different. U44069 and cyanide binding to TXAS exhibited monophasic kinetics, in contrast to the biphasic kinetics found for imidazole and clotrimazole. Analysis of k obs versus ligand concentrations further indicated that cyanide underwent a onestep binding process, whereas U44069, imidazole, and clotrimazole underwent two-step binding processes.
Interestingly, the binding mechanisms of those ligands involved in the two-step binding processes are distinctly different. U44069 first binds TXAS, but not heme iron, and then replaces the original heme ligand. The two nitrogen-based ligands, nonetheless, bind heme iron first and then undergo a conformational change before they reach equilibrium. Cyanide, which is charged but is the smallest molecule tested, had the lowest on-rate constant (2.4 M Ϫ1 s
). This low rate constant compared with other hemoproteins is likely due to the strong electron-donating thiolate ligand. On the other hand, clotrimazole, although much bulkier than imidazole, had a higher onrate constant (8. Ϫ1 s Ϫ1 for imidazole and clotrimazole, respectively). These results indicated that the TXAS active site is both hydrophobic and spacious, consistent with our previously reported findings (13) .
Classical eukaryotic P450s catalyze hydroxylation reactions at a very slow rate with k cat of 1-10 mol of product formed/min/ mol of P450 (21). Many prokaryotic P450s, however, have somewhat higher catalytic activities. For example, P450 cam catalyzes the reaction at a rate of ϳ1900 mol/min/mol of protein (22) , and so does P450BM-3 (23), a soluble protein in which the reductase domain is naturally fused to the oxygenase domain. For the "non-classical" P450s such as allene-oxide synthase and nitric-oxide reductase that do not need reductase for catalysis, SCHEME 2 the turnover numbers seems to be much higher. Allene-oxide synthase, a P450 acting as a dehydrase which converts lipid hydroperoxide to allene oxide, appears to form product at a rate of Ͼ60,000 mol/min/mol of protein (24 (27) , TXAS should be considered as a very efficient catalyst. It should also be noted that many P450s including P450 cam can act as non-classical P450s and convert PGH 2 to MDA and HHT, but not TXA 2 , without reductase, molecular oxygen, or any electron donor (11) . Their "HHT/ MDA synthase" activities, nonetheless, are much lower than TXAS. A recent report showed that four microsomal P450s (P4501A2, 2B1, 2E1, and 3A4) had K d for U44069 of ϳ200 M and when assayed at 50 M PGH 2 , their catalytic activities were 1-10 min Ϫ1 (28) . It would appear that PGH 2 was readily converted to MDA and HHT by heme in the context of P450 where a hydrophobic environment is present. A study of chemical models for heme-catalyzed PGH 2 reactions showed that 9% of HHT was formed in a phosphate buffer, whereas 33% of HHT was formed in acetonitrile, a less polar solvent (11) . TXAS is more efficient in HHT/MDA synthesis not only because its active site is hydrophobic but it also has a greater affinity for PGH 2 . Furthermore, several TXAS active site amino acid residues, as we have previously shown (29) , may be involved in the reaction. It is intriguing to note that prostacyclin synthase, although it has a high affinity for PGH 2 (K d is ϳ10 M), does not catalyze HHT/MDA formation (11) . What structural elements determine the HHT/MDA activity of P450 remains a challenging topic.
In this study, the rate constant of each catalytic step, i.e. PGH 2 to TXA 2 or MDA/HHT, is estimated to be ϳ15,000 s Ϫ1 . The half-life of the intermediate(s) at 23°C is therefore much less than the dead-time of the stopped-flow apparatus (ϳ1.5 ms). Furthermore, the rate constant of substrate binding is 12-20 ϫ 10 6 M Ϫ1 s Ϫ1 and the in vivo binding constant could be calculated if the cellular PGH 2 concentration was known. To the best of our knowledge, cellular PGH 2 concentration has not been reported due in part to the instability of PGH 2 in aqueous solution. However, concentrations of arachidonic acid, the substrate for prostaglandin H synthase, in many inflammatory blood cells and lung tissues were less than 10 M (30, 31) . In pancreatic islets, cellular un-esterified arachidonate concentrations of 38 -75 M were reported under glucose-induced conditions. But the maximally effective concentration, including exogenous arachidonic acid, was 30 -40 M (32). Since arachidonic acid is a substrate for many other pathways in addition to prostaglandin H synthase, it is probably safe to assume that the cellular PGH 2 concentration is generally less than 40 M. If that is the case, the substrate-binding rate constant for TXAS in the physiological conditions would be less than 800 s
, and this value is much smaller than the other forward rate constants. We therefore conclude that the substrate-binding step is the rate-limiting step in the TXAS-catalyzed reaction.
P450s were also classified according to the identity of their electron donors. Class I P450s require both ferredoxin and ferredoxin reductase for electron transfer, whereas Class II P450s require only a P450 reductase (33) . In both Class I and Class II P450s, the rate-limiting step of the overall reaction is at the stage of the second electron transfer to the heme center. Class III P450s that do not require any reductase, are not well characterized regarding their kinetic mechanisms. An elegant study on P450 nor , a Class III P450, revealed that binding of NO and NADH substrates were fast to form the intermediate I, an NO-bound two-electron reduced species (25) . The intermediate I was slowly converted to the products. The rate-limiting step of P450 nor is thus in the chemical steps. In contrast to other P450s, the rate-limiting step of TXAS is at the step of substrate binding. To the best of our knowledge, this kinetic mechanism is the first example of Class III P450s in which substrate binding is the rate-limiting step.
